Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SLN | US
0.24
1.30%
Healthcare
Biotechnology
30/06/2024
04/10/2024
18.64
19.28
19.76
18.49
Silence Therapeutics plc a biotechnology company focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology cardiovascular and other rare and metabolic indications. The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver. Its siRNA molecules to harness the body's natural mechanism of RNA interference and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company develops SLN360 which is in phase 2 clinical development to reduce high levels of lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia and Phase I clinical trials for the treatment of myelodysplastic syndrome; and polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover develop and commercialize small interfering siRNA therapeutics for the treatment of cardiovascular renal metabolic and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform as well as the company also collab with Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London the United Kingdom.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
34.3%1 month
26.6%3 months
50.0%6 months
47.7%-
-
5.70
0.00
0.00
-5.78
25.25
-
-48.16M
933.49M
933.49M
-
-3.06K
-
-93.40
-64.28
1.35
0.99
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
2.62
Range1M
2.98
Range3M
7.22
Rel. volume
0.79
Price X volume
2.69M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
AnaptysBio Inc | ANAB | Biotechnology | 33.98 | 1.03B | -2.91% | n/a | 3835.68% |
Aurinia Pharmaceuticals Inc | AUPH | Biotechnology | 7.12 | 1.02B | 0.00% | n/a | 23.58% |
Pharvaris B.V | PHVS | Biotechnology | 18.2 | 982.94M | -0.66% | n/a | 0.04% |
Array BioPharma Inc | ARRY | Biotechnology | 6.45 | 979.92M | 0.62% | 67.30 | 117.68% |
Sana Biotechnology Inc. Common Stock | SANA | Biotechnology | 4.23 | 941.03M | -2.98% | n/a | 29.02% |
Prothena Corporation plc | PRTA | Biotechnology | 16.86 | 906.74M | 1.08% | n/a | 2.08% |
Zymeworks Inc | ZYME | Biotechnology | 12.57 | 893.07M | 1.45% | n/a | 4.94% |
Applied Therapeutics Inc | APLT | Biotechnology | 7.7 | 884.31M | -8.22% | n/a | 0.30% |
Cronos Group Inc | CRON | Biotechnology | 2.24 | 856.31M | 3.70% | n/a | 0.19% |
iShares $ Corp Bond ETF USD Dist | LQDA | Biotechnology | 10.03 | 846.31M | 0.25% | n/a | 4.70% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -5.78 | 0.76 | Cheaper |
Ent. to Revenue | 25.25 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 5.70 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 50.02 | 74.67 | Lower Risk |
Debt to Equity | 0.00 | -1.82 | Expensive |
Debt to Assets | 0.00 | 0.26 | Cheaper |
Market Cap | 933.49M | 3.73B | Emerging |